NovaBridge Biosciences Total Liabilities Growth & History (NBP)

NovaBridge Biosciences's total liabilities was $29.6M for fiscal 2025.

View full NovaBridge Biosciences company overview

NovaBridge Biosciences annual total liabilities history

NovaBridge Biosciences annual total liabilities

Fiscal yearPeriod endedTotal liabilitiesChangeGrowth
20252025-12-31$29.6M$18.1M+156.78%
20242024-12-31$11.5M−$114.8M−90.88%
20232023-12-31$126.3M−$42.4M−25.12%
20222022-12-31$168.7M$5.3M+3.23%
20212021-12-31$163.5M$55.2M+50.93%
20202020-12-31$108.3M$12.3M+12.85%
20192019-12-31$96.0M

NovaBridge Biosciences total liabilities trends

Over the last five fiscal years, NovaBridge Biosciences's total liabilities decreased from $108.3M to $29.6M, a change of −$78.7M. The latest reported quarter, Q2 2026, shows $30.4M.

About the metric

What total liabilities mean

Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.

Calculation and source

SEC-reported and calculated total liabilities

TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review NovaBridge Biosciences source filings ↗

Community posts

It’s quiet here.

No posts about NBP yet. Start the conversation.

Write the first post